Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer

Vincent K. Lam; Patrick M. Forde

doi:10.1016/j.jtho.2020.08.013

Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer

Vincent K. Lam, Patrick M. Forde

School of Medicine

Research output: Contribution to journal › Editorial › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1556-1558
Number of pages	3
Journal	Journal of Thoracic Oncology
Volume	15
Issue number	10
DOIs	https://doi.org/10.1016/j.jtho.2020.08.013
State	Published - Oct 2020

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.jtho.2020.08.013

Cite this

@article{b84d65aa109b4bcbb3d995a38e2fee8e,

title = "Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer",

author = "Lam, {Vincent K.} and Forde, {Patrick M.}",

note = "Funding Information: Disclosure: Dr. Lam reports receiving personal fees from Seattle Genetics, Takeda Pharmaceuticals, and Bristol-Myers Squibb and grants from Bristol-Myers Squibb outside of the submitted work. Dr. Forde reports receiving grants and other fees from AstraZeneca and Bristol-Myers Squibb; other fees from Johnson & Johnson; and grants from Corvus and Kyowa outside of the submitted work.",

year = "2020",

month = oct,

doi = "10.1016/j.jtho.2020.08.013",

language = "English (US)",

volume = "15",

pages = "1556--1558",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "10",

}

TY - JOUR

T1 - Another Brick in the Wall

T2 - Sintilimab Plus Chemotherapy in Advanced Lung Cancer

AU - Lam, Vincent K.

AU - Forde, Patrick M.

N1 - Funding Information: Disclosure: Dr. Lam reports receiving personal fees from Seattle Genetics, Takeda Pharmaceuticals, and Bristol-Myers Squibb and grants from Bristol-Myers Squibb outside of the submitted work. Dr. Forde reports receiving grants and other fees from AstraZeneca and Bristol-Myers Squibb; other fees from Johnson & Johnson; and grants from Corvus and Kyowa outside of the submitted work.

PY - 2020/10

Y1 - 2020/10

UR - http://www.scopus.com/inward/record.url?scp=85091677065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091677065&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2020.08.013

DO - 10.1016/j.jtho.2020.08.013

M3 - Editorial

C2 - 32981596

AN - SCOPUS:85091677065

SN - 1556-0864

VL - 15

SP - 1556

EP - 1558

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 10

ER -

Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this